Rosuvastatin (Crestor)

FDA Approved

HMG-CoA Reductase Inhibitor | Statin for Lipid Management

Weight: 481.54 Da

Half-life: ~19 hours

4 studies

2015 latest

3 recent

FDA Approved

Dose 5-20 mg/day

Frequency Once daily

Cycle Ongoing (chronic use or duration of AAS cycle)

Storage Room temperature (68-77F). Protect from moisture and light.

Accumulation Plotter

Community Research

Join others researching Rosuvastatin — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Rosuvastatin is the most potent statin currently available, offering the greatest LDL cholesterol reduction per milligram among all HMG-CoA reductase inhibitors. FDA-approved in 2003 under the brand name Crestor, it rapidly became one of the most prescribed medications worldwide for hyperlipidemia and cardiovascular risk reduction. Rosuvastatin is particularly popular in the anabolic steroid community, where it is widely used to manage lipid disturbances caused by androgenic-anabolic steroids (AAS), especially oral compounds like oxandrolone, stanozolol, and methandrostenolone that are notorious for dramatically worsening lipid profiles. Its long 19-hour half-life allows convenient once-daily dosing, and its hydrophilic nature gives it hepatic selectivity with a potentially lower incidence of muscle-related side effects compared to lipophilic statins like atorvastatin and simvastatin. The JUPITER trial demonstrated that rosuvastatin significantly reduces cardiovascular events even in individuals with normal LDL but elevated high-sensitivity C-reactive protein (hsCRP), highlighting its anti-inflammatory properties beyond pure lipid lowering.

Mechanism of Action

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface. The increased density of LDL receptors enhances clearance of LDL cholesterol and its precursors (VLDL and IDL) from the bloodstream. Rosuvastatin has the highest binding affinity for HMG-CoA reductase among all available statins, which accounts for its superior potency. Beyond lipid lowering, rosuvastatin exerts pleiotropic effects that contribute to cardiovascular protection: improvement of endothelial function via increased nitric oxide bioavailability, reduction of vascular inflammation (lowering hsCRP by 30-50%), stabilization of atherosclerotic plaques, decreased oxidative stress, and modest antithrombotic effects. In the context of AAS use, rosuvastatin counteracts the characteristic lipid derangement pattern caused by androgens -- namely suppressed HDL cholesterol and elevated LDL cholesterol -- by directly reducing LDL production and, to a lesser extent, raising HDL through unclear mechanisms thought to involve apolipoprotein A-I upregulation.

01 Most potent statin available, with LDL reductions of 45-63% depending on dose

02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day

03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL

04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit

05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects

06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression

07 Proven cardiovascular event and mortality reduction in large-scale clinical trials

08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG

Molecular Data

Molecular Weight

481.54 Da

Type

Synthetic statin (C22H28FN3O6S-Ca)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

Lipid Management

Primary Hyperlipidemia most effective

First-line treatment for elevated LDL cholesterol and mixed dyslipidemia. Rosuvastatin 10-20 mg achieves LDL reductions of 45-55%, outperforming equivalent doses of other statins. Particularly appropriate when aggressive LDL lowering is required or when patients have not reached lipid targets on less potent statins.

AAS-Induced Dyslipidemia effective

Widely used off-label to manage lipid disturbances caused by anabolic steroid cycles, especially oral AAS (oxandrolone, stanozolol, methandrostenolone) that severely impact lipid profiles. Typical on-cycle doses of 5-10 mg daily can meaningfully reduce LDL elevation, though HDL suppression caused by androgens is only partially mitigated. Most effective when started before or at the beginning of a cycle rather than reactively.

Cardiovascular Risk Reduction most effective

Proven to reduce major cardiovascular events including myocardial infarction, stroke, and cardiovascular death. The JUPITER trial showed a 44% reduction in major cardiovascular events in apparently healthy individuals with elevated hsCRP. Particularly relevant for long-term AAS users who accumulate cardiovascular risk over time.

Prevention

Primary Prevention in High-Risk Individuals effective

Indicated for cardiovascular risk reduction in individuals without established cardiovascular disease but with risk factors such as dyslipidemia, family history, or elevated inflammatory markers. The JUPITER trial established benefit even in patients with LDL below 130 mg/dL if hsCRP was elevated above 2 mg/L.

Atherosclerosis Progression Slowing effective

The METEOR trial demonstrated that rosuvastatin 40 mg significantly slowed progression of carotid intima-media thickness compared to placebo in low-risk patients with subclinical atherosclerosis. Suggests benefit in slowing vascular damage that may accumulate in chronic AAS users.

Dosing Protocols

Rosuvastatin is administered exclusively via the oral route as film-coated tablets. Unlike some statins that must be taken in the evening due to short half-lives, rosuvastatin's long 19-hour half-life allows dosing at any time of day without loss of efficacy. It can be taken with or without food, though food modestly reduces the rate (but not extent) of absorption. Bioavailability is approximately 20%, with the liver being the primary site of action. Rosuvastatin undergoes minimal hepatic metabolism via CYP2C9 (with minor CYP2C19 involvement), resulting in fewer drug-drug interactions compared to statins metabolized by CYP3A4.

Goal	Dose	Frequency	Route
On-Cycle Lipid Management (AAS Use)	5-10 mg/day	Once daily	Oral
Aggressive Lipid Lowering	10-20 mg/day	Once daily	Oral
Standard Hyperlipidemia (Non-AAS)	5-20 mg/day	Once daily	Oral

Interactions

Ezetimibe

Rosuvastatin and ezetimibe target complementary pathways in cholesterol metabolism -- rosuvastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination (available as the fixed-dose product Roszet) provides an additional 15-20% LDL reduction beyond rosuvastatin alone. Particularly useful for AAS users whose lipids remain elevated despite statin monotherapy, or for those running especially hepatotoxic oral stacks.

synergistic

Oxandrolone

Rosuvastatin is commonly co-administered with oxandrolone (Anavar) to counteract the significant lipid damage caused by this oral AAS. Oxandrolone is well known to suppress HDL by 40-50% and elevate LDL substantially. While rosuvastatin effectively addresses the LDL elevation, it only partially mitigates HDL suppression. Starting rosuvastatin before or concurrently with oxandrolone is recommended rather than waiting for bloodwork to deteriorate.

compatible

Testosterone

No significant negative interactions. Supraphysiological testosterone modestly worsens lipid profiles (particularly HDL suppression), and rosuvastatin can help maintain healthier lipid levels during testosterone cycles or TRT. Both are commonly used together in the PED community. Rosuvastatin does not interfere with testosterone's anabolic effects or endocrine activity.

compatible

What to Expect

Week 1-2

LDL cholesterol begins to decrease as hepatic LDL receptor upregulation takes effect. Measurable lipid changes can be detected on bloodwork within 1 week of initiation. Some users may notice muscle soreness or mild GI discomfort during initial adaptation, though most are asymptomatic.

Week 2-4

LDL reduction reaches approximately 75-90% of maximum effect. Most users will see significant LDL improvement on mid-cycle bloodwork taken at this point. hsCRP levels begin to decline, reflecting the anti-inflammatory pleiotropic effects. Any initial muscle discomfort typically resolves.

Month 1-3

Full steady-state lipid-lowering effect achieved. LDL reduction of 45-63% depending on dose. HDL may increase modestly (8-14%), though this benefit may be blunted by concurrent AAS use. Triglycerides reduced by 10-35%. This is the ideal window to repeat comprehensive lipid panels to assess efficacy and adjust dosing if needed.

Month 3-6

Sustained lipid control with stable LDL, HDL, and triglyceride levels. Inflammatory markers (hsCRP) continue to improve. Long-term cardiovascular protection mechanisms (plaque stabilization, endothelial function improvement) become increasingly relevant. Liver enzymes should be checked if not already done.

Month 6+

Ongoing cardiovascular risk reduction. For chronic AAS users, continued statin use between cycles may be warranted if baseline lipids remain suboptimal. Annual monitoring of lipid panel, liver enzymes, fasting glucose, and creatine kinase (if symptomatic) is recommended.

Side Effects & Safety

Common Side Effects

Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea

Stop Signs - Discontinue if:

Unexplained severe muscle pain, tenderness, or weakness, especially with fever or malaise (possible rhabdomyolysis)
Dark brown or cola-colored urine (myoglobinuria suggesting rhabdomyolysis)
Jaundice, severe right upper quadrant abdominal pain, or markedly elevated liver enzymes (>3x ULN)
Severe allergic reaction (rash, swelling, difficulty breathing)

Contraindications

Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg

Quality Checklist

Good Signs

Pharmaceutical-grade product from established manufacturer with valid NDC number
Proper labeling with dosage strength, lot number, and expiration date
Tablets are uniform in appearance with intact film coating
Prescribed by licensed physician with appropriate lipid workup
Generic rosuvastatin from reputable manufacturer (bioequivalent to brand Crestor)

Warning Signs

Sourced from unverified international pharmacies without regulatory oversight
Compounded liquid formulations without verified potency testing
UGL (underground lab) sourced statins sold alongside AAS -- variable quality and dosing accuracy

Bad Signs

Tablets that are crumbling, chipped, discolored, or missing film coating
Product past its expiration date
No labeling or incorrect dosage strength labeling
Sourced without any verification of identity or purity

References

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER Trial)

Ridker, P.M., Danielson, E., Fonseca, F.A., et al.

The New England Journal of Medicine (2008)

Landmark trial of 17,802 apparently healthy individuals with LDL <130 mg/dL and hsCRP >2 mg/L. Rosuvastatin 20 mg reduced major cardiovascular events by 44%, LDL by 50%, and hsCRP by 37% compared to placebo. Trial was stopped early due to unequivocal benefit.
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia (PLUTO Trial)

Avis, H.J., Hutten, B.A., Gagne, C., et al.

Journal of the American College of Cardiology (2010)

Demonstrated the dose-dependent LDL-lowering efficacy and safety of rosuvastatin across different populations, supporting its position as the most potent available statin with LDL reductions of 38-50% at 5-20 mg doses.
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis (METEOR Trial)

Crouse, J.R., Raichlen, J.S., Riley, W.A., et al.

JAMA (2007)

Rosuvastatin 40 mg significantly slowed progression of maximum carotid intima-media thickness compared to placebo in asymptomatic individuals with low Framingham risk scores but evidence of subclinical atherosclerosis, demonstrating anti-atherosclerotic benefit beyond lipid lowering.
Comparative effectiveness of HMG-CoA reductase inhibitors (statins) for lipid lowering

Adams, S.P., Tsang, M., Wright, J.M.

Cochrane Database of Systematic Reviews (2015)

Systematic review confirming rosuvastatin as the most potent statin for LDL reduction. At equivalent doses, rosuvastatin lowered LDL 5-8% more than atorvastatin and 12-18% more than simvastatin. Rosuvastatin 5 mg was approximately equivalent to atorvastatin 10 mg in LDL lowering.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.